AbbVie

Allergan PLC
Chicago, Illinois
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Abbvie is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Abbvie embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.

View Full Corporate Bias Ratings Report

Board Bias

Expand Summary

CEO of AbbVie

Richard A. Gonzalez

Richard A. Gonzalez

Summary:

Headquartered in Chicago, Illinois, AbbVie is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Richard A. Gonzalez serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $101,550 to Republican causes and $84,950 to Democratic causes. Under their tenure, AbbVie currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:

$101,550

$84,950

Republican

Democrat

China Risk Database

Expand Summary

Number of Facilities: 4

Total Export Dollars: $164,035

View Full China Report

Total Estimated Sanctions (3-year Avg.)

$169,620,585

Average Annual Revenue

Global

$45,537,000,000

China Revenue

1.12%

$511,666,667

Annual Average of Total Assets

Global

$116,240,666,667

China Assets

1.15%

$1,334,750,301

Shareholder Proposals

Expand Summary

Date
ESG Category
Proponent
Summary of ResolutionMgmt RecTotal Vote % in Favor
5/3/24Zevin Asset Management on behalf of Alyson PyetteStockholder Proposal on LobbyingAgainstN/A
5/3/24Friends Fiduciary Corporation and Co-filers Mercy Investment ServicesStockholder Proposal on Patent ProcessAgainstN/A
5/3/24John Chevedden on behalf of Kenneth SteinerSimple Majority VoteAgainstN/A
5/5/23GovernanceJohn CheveddenSimple Majority VotingAgainst53.90%
5/5/23GovernanceDana Investment AdvisersIssue a Report on LobbyingAgainst35.70%
5/5/23GovernanceFriends Fiduciary CorporationIssue a Report on Patent ProcessAgainst29.00%
5/5/23GovernanceAs You SowReport on Political SpendingAgainst14.90%
5/6/22GovernanceKenneth SteinerShareholder Ratification of Termination Pay Exceeding 2.99x Total PayAgainst50.10%
5/6/22SocialAs You SowReport on Political SpendingAgainst39.32%
5/6/22GovernanceFriends Fiduciary Corp.Board Oversight of Risks Related to Anticompetitive PracticesAgainst32.82%
5/6/22GovernanceRhode Island Employees Retirement SystemIndependent Board ChairAgainst30.18%
Generate Reports
Clear
Toast